NCT03219320 - Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy | Biotech Hunter

Enrollment

301

Participants

Timeline

Start Date

June 27, 2017

Primary Completion Date

November 2, 2018

Study Completion Date

November 2, 2018

Conditions

Diabetic Peripheral Neuropathy

Interventions

DRUG

NYX-2925

NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).

DRUG

Placebo

Matching Placebo capsules.

Trial Locations (35)

14618

Aptinyx Clinical Site, Rochester

23510

Aptinyx Clinical Site, Norfolk

30033

Aptinyx Clinical Site, Decatur

31904

Aptinyx Clinical Site, Columbus

32801

Aptinyx Clinical Site, Orlando

32806

Aptinyx Clinical Site, Orlando

33009

Aptinyx Clinical Site, Hallandale

33012

Aptinyx Clinical Site, Miami

33126

Aptinyx Clinical Site, Miami

33175

Aptinyx Clinical Site, Miami

33401

Aptinyx Clinical Site, West Palm Beach

33458

Aptinyx Clinical Site, Jupiter

33511

Aptinyx Clinical Site, Brandon

33603

Aptinyx Clinical Site, Tampa

33912

Aptinyx Clinical Site, Fort Myers

34201

Aptinyx Clinical Site, Bradenton

34761

Aptinyx Clinical Site, Ocoee

37388

Aptinyx Clinical Site, Tullahoma

37909

Aptinyx Clinical Site, Knoxville

38119

Aptinyx Clinical Site, Memphis

45439

Aptinyx Clinical Site, Dayton

60422

Aptinyx Clinical Site, Flossmoor

63042

Aptinyx Clinical Site, Hazelwood

75024

Aptinyx Clinical Site, Plano

77058

Aptinyx Clinical Site, Houston

78731

Aptinyx Clinical Site, Austin

83642

Aptinyx Clinical Site, Meridian

85053

Aptinyx Clinical Site, Phoenix

90404

Aptinyx Clinical Site, Santa Monica

92480

Aptinyx Clinical Site, Tustin

92801

Aptinyx Clinical Site, Anaheim

92860

Aptinyx Clinical Site, Norco

93710

Aptinyx Clinical Site, Fresno

06320

Aptinyx Clinical Site, New London

08009

Aptinyx Clinical Site, Berlin